IgE CH3 PEPTIDE VACCINE
PROBLEM TO BE SOLVED: To provide novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders.SOLUTION: The antigenic IgE peptide is linked to the immunogenic carrier (VLP) via a linker. The im...
Saved in:
Main Authors | , , , , , , , , |
---|---|
Format | Patent |
Language | English Japanese |
Published |
08.09.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | PROBLEM TO BE SOLVED: To provide novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders.SOLUTION: The antigenic IgE peptide is linked to the immunogenic carrier (VLP) via a linker. The immunogenic composition of the present invention comprises at least one adjuvant. The adjuvant is an immunostimulatory oligonucleotide, and more preferably a CpG oligonucleotide. The invention further relates to methods for producing these medicaments, methods for producing immunogenic compositions and pharmaceutical compositing thereof, and their use in medicine.SELECTED DRAWING: None
【課題】IgE媒介性障害を予防、治療、または軽減するための、好ましくは免疫原性担体に連結された抗原性IgEペプチドを含む新規の免疫原の提供。【解決手段】抗原性IgEペプチドはリンカーを介して免疫原性担体(VLP)に結合される。また対象免疫原性組成物は少なくとも1つのアジュバンドを含む。アジュバンドは、免疫賦活性オリゴヌクレオチド、より好ましくはCpGオリゴヌクレオチドである。更に、これらの薬物、その免疫原性組成物および医薬組成物を製造するための方法、および医薬におけるこれらの使用。【選択図】なし |
---|---|
Bibliography: | Application Number: JP20160039991 |